Search

Timothy W Noblitt

from Carmel, IN
Age ~60
Get Report
Also known as:
Tim W Noblitt, Timothy W Noblit, Timothy Nizamoff
Phone and address:
321 4Th St, Carmel, IN 46033
(317) 566-1384
Related to:
Samuel Noblitt, 24Lee M Williams, 80Elizabeth R ShoresAngela N Shores, 60Lynda M Williams, 50Christoph M Morris, 34Robert D Shores, 87Amy M Noblitt, 57Patricia L Williams, 86Christopher S Williams, 54Matthew Davison, 57Margaret A Williams
Connected to:
Sam W Noblitt, 60Robert J Nobmann, 90Jeannette Nobo, 65Michael A Nobo, 40Claribel Noboa, 42Eliza Noboa, 54Felipe H Noboa, 40Jay V Noboa, 56Maritza L Noboa, 41Massiel S Noboa, 45

Timothy Noblitt Phones & Addresses

  • 321 4Th St, Carmel, IN 46033 (317) 566-1384
  • 11515 Charleston Pkwy, Fishers, IN 46038 (317) 570-8525
  • 5318 Rosslyn Ave, Indianapolis, IN 46220
  • 2650 Manker St, Indianapolis, IN 46203
  • 9018 Sunny Ridge Dr, Indianapolis, IN 46250 (317) 915-1589
  • 2905 Warman Ave, Indianapolis, IN 46222 (317) 926-6151
  • Columbus, IN
  • 321 4Th Ct E, Carmel, IN 46033 (317) 566-1384

Work

Position: Professional/Technical

Education

Degree: Associate degree or higher

Emails

t***[email protected]

Industries

Pharmaceuticals

Resumes

Resumes

Timothy Noblitt Photo 1

Process Improvement

View page
Location:
Indianapolis, Indiana Area
Industry:
Pharmaceuticals

Publications

Us Patents

Use Of Lp82 To Treat Hematopoietic Disorders

View page
US Patent:
7101539, Sep 5, 2006
Filed:
Feb 14, 2002
Appl. No.:
10/467431
Inventors:
Josef Georg Heuer - Indianapolis IN, US
Ling Liu - Carmel IN, US
Timothy W. Noblitt - Fishers IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 38/18
A61K 38/20
C07K 14/475
C07K 14/54
US Classification:
424 851, 4241981, 514 2, 514 12, 530300, 530351, 530399
Abstract:
The present invention relates to a method of using a mammalian gene sequence and polypeptides encoded thereby to treat mammalian hematopoietic disorders. More specifically the present invention relates to methods of using compositions comprising at least one LP82 agonist, LP82 antagonist, LP82 polynucleotide, LP82 polypeptide, and/or LP82 antibody for the prevention and/or treatment of mammalian hematopoietic disorders, including, but not limited to, anemia, leukemia, and hematopoietic conditions caused by bone marrow transplantation or chemo-/radiation therapy.

Flint Polypeptide Analogs

View page
US Patent:
6965012, Nov 15, 2005
Filed:
Mar 20, 2000
Appl. No.:
09/936024
Inventors:
Gerald Wayne Becker - Fishers IN, US
Fredric Jay Cohen - Newtown PA, US
John Edward Hale - Fishers IN, US
Radmila Micanovic - Indianapolis IN, US
Christy Michelle Newton - Indianapolis IN, US
Timothy Wayne Noblitt - Fishers IN, US
Radhakrishnan Rathnachalam - Carmel IN, US
Sheng-Hung Rainbow Tschang - Carmel IN, US
Derrick Ryan Witcher - Fishers IN, US
Victor John Wroblewski - Carmel IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07K014/705
C07H021/04
US Classification:
530350, 536 235
Abstract:
Disclosed are polypeptide analogs of FLINT, polydeoxynucleotides encoding FLINT analogs, and methods of using FLINT analogs and polydeoxynucleotides. The FLINT analogs of the invention include polypeptides having the amino acid sequence of FLINT, modified at one or more positions with amino acid substitutions, and include fragments thereof, as well as Fc fusions comprising FLINT and FLINT analogs.
Control profile
Timothy W Noblitt from Carmel, IN, age ~60 Get Report